Genetic aberrations of signaling pathways in lymphomagenesis: Revelations from next generation sequencing studies

Seminars in Cancer Biology

Volumn 23, Issue 6 Part A, 2013, Pages 422-430

  Rossi, Davide ^a   Ciardullo, Carmela ^a   Gaidano, Gianluca ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Chronic lymphocytic leukemia; Hairy cell leukemia; Lymphoma; Mutation; Next generation sequencing

Indexed keywords

B LYMPHOCYTE RECEPTOR; BIRC3 PROTEIN; BREAKPOINT CLUSTER REGION PROTEIN; CARD11 PROTEIN; CD79A ANTIGEN; CD79B ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYELOID DIFFERENTIATION FACTOR 88; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH2 RECEPTOR; TOLL LIKE RECEPTOR; TUMOR PROTEIN; UNCLASSIFIED DRUG;

BCR GENE; BINDING AFFINITY; BINDING SITE; BIRC3 GENE; CARCINOGENESIS; CARD11 GENE; DISEASE ACTIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; HUMAN; LYMPHOMA; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MYD88 GENE; NEXT GENERATION SEQUENCING; NOTCH1 GENE; NOTCH2 GENE; ONCOGENE; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

CHRONIC LYMPHOCYTIC LEUKEMIA; HAIRY CELL LEUKEMIA; LYMPHOMA; MUTATION; NEXT GENERATION SEQUENCING;

HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; LYMPHOMA; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; MUTATION; MYELOID DIFFERENTIATION FACTOR 88; NF-KAPPA B; PROTO-ONCOGENE PROTEINS B-RAF; RECEPTOR, NOTCH2; SIGNAL TRANSDUCTION;

EID: 84887615858     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2013.04.002     Document Type: Review

References (70)

1. Swerdlow S.H., Campo E., Harris N.L., Jaffe E.S., Pileri S., Stein H., et al. WHO classification of tumours of haematopoietic abd lymphoid tissues 2008, IARC, Lyon. 4th ed.
2. Lenz G., Davis R.E., Ngo V.N., Lam L., George T.C., Wright G.W., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319:1676-1679.
3. Compagno M., Lim W.K., Grunn A., Nandula S.V., Brahmachary M., Shen Q., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459:717-721.
4. Davis R.E., Ngo V.N., Lenz G., Tolar P., Young R.M., Romesser P.B., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463:88-92.
5. Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics 2010, 42:181-185.
6. Challa-Malladi M., Lieu Y.K., Califano O., Holmes A.B., Bhagat G., Murty V.V., et al. Combined genetic inactivation of β2-Microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
7. Fabbri G., Rasi S., Rossi D., Trifonov V., Khiabanian H., Ma J., et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. Journal of Experimental Medicine 2011, 208:1389-1401.
8. Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476:298-303.
9. Ngo V.N., Young R.M., Schmitz R., Jhavar S., Xiao W., Lim K.H., et al. Oncogenically active MYD88 mutations in human lymphoma. Nature 2011, 470:115-119.
10. Pasqualucci L., Dominguez-Sola D., Chiarenza A., Fabbri G., Grunn A., Trifonov V., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471:189-195.
11. Pasqualucci L., Trifonov V., Fabbri G., Ma J., Rossi D., Chiarenza A., et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nature Genetics 2011, 43:830-837.
12. Puente X.S., Pinyol M., Quesada V., Conde L., Ordóñez G.R., Villamor N., et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 2011, 475:101-105.
13. Quesada V., Conde L., Villamor N., Ordóñez G.R., Jares P., Bassaganyas L., et al. Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genetics 2011, 44:47-52.
14. Rossi D., Bruscaggin A., Spina V., Rasi S., Khiabanian H., Messina M., et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood 2011, 118:6904-6908.
15. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., et al. BRAF mutations in hairy-cell leukemia. New England Journal of Medicine 2011, 364:2305-2315.
16. Wang L., Lawrence M.S., Wan Y., Stojanov P., Sougnez C., Stevenson K., et al. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. New England Journal of Medicine 2011, 365:2497-2506.
17. Kiel M.J., Velusamy T., Betz B.L., Zhao L., Weigelin H.G., Chiang M.Y., et al. Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. Journal of Experimental Medicine 2012, 209:1553-1565.
18. Rossi D., Trifonov V., Fangazio M., Bruscaggin A., Rasi S., Spina V., et al. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. Journal of Experimental Medicine 2012, 209:1537-1551.
19. Kridel R., Meissner B., Rogic S., Boyle M., Telenius A., Woolcock B., et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 2012, 119:1963-1971.
20. Lohr J.G., Stojanov P., Lawrence M.S., Auclair D., Chapuy B., Sougnez C., et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proceedings of the National Academy of Sciences of the United States of America 2012, 109:3879-3884.
21. Love C., Sun Z., Jima D., Li G., Zhang J., Miles R., et al. The genetic landscape of mutations in Burkitt lymphoma. Nature Genetics 2012, 44:1321-1325.
22. Richter J., Schlesner M., Hoffmann S., Kreuz M., Leich E., Burkhardt B., et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nature Genetics 2012, 44:1316-1320.
23. Rossi D., Fangazio M., Rasi S., Vaisitti T., Monti S., Cresta S., et al. Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. Blood 2012, 119:2854-2862.
24. Schmitz R., Young R.M., Ceribelli M., Jhavar S., Xiao W., Zhang M., et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012, 490:116-120.
25. Treon S.P., Xu L., Yang G., Zhou Y., Liu X., Cao Y., et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. New England Journal of Medicine 2012, 367:826-833.
26. Meissner B., Kridel R., Lim R.S., Rogic S., Tse K., Scott D.W., et al. The E3 ubiquitin ligase UBR5 is recurrently mutated in mantle cell lymphoma. Blood 2013, [Epub ahead of print]. 10.1182/blood-2013-01-478834.
27. Zhang J., Grubor V., Love C.L., Banerjee A., Richards K.L., Mieczkowski P.A., et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America 2013, 110:1398-1403.
28. Thome M., Charton J.E., Pelzer C., Hailfinger S. Antigen receptor signaling to NF-kappaB via CARMA1, BCL10, and MALT1. Cold Spring Harbor Perspectives in Biology 2010, 2:a003004.
29. Woyach J.A., Johnson A.J., Byrd J.C. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 2012, 120:1175-1184.
30. Kurosaki T., Hikida M. Tyrosine kinases and their substrates in B lymphocytes. Immunological Reviews 2009, 228:132-148.
31. Rosenwald A., Wright G., Chan W.C., Connors J.M., Campo E., Fisher R.I., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. New England Journal of Medicine 2002, 346:1937-1947.
32. Gauld S.B., Dal Porto J.M., Cambier J.C. B cell antigen receptor signaling: roles in cell development and disease. Science 2002, 296:1641-1642.
33. Rawlings D.J., Sommer K., Moreno-García M.E. The CARMA1 signalosome links the signalling machinery of adaptive and innate immunity in lymphocytes. Nature Reviews Immunology 2006, 6:799-812.
34. Limon J.J., Fruman D.A. B cell receptor signaling: picky about PI3Ks. Science Signaling 2010, 3:pe25.
35. Kee B.L. E and ID proteins branch out. Nature Reviews Immunology 2009, 9:175-184.
36. Rawlings D.J., Schwartz M.A., Jackson S.W., Meyer-Bahlburg A. Integration of B cell responses through Toll-like receptors and antigen receptors. Nature Reviews Immunology 2012, 12:282-294.
37. Rossi D., Deaglio S., Dominguez-Sola D., Rasi S., Vaisitti T., Agostinelli C., et al. Alteration of BIRC3 and multiple other NF-κB pathway genes in splenic marginal zone lymphoma. Blood 2011, 118:4930-4934.
38. Yan Q., Huang Y., Watkins A.J., Kocialkowski S., Zeng N., Hamoudi R.A., et al. BCR and TLR signaling pathways are recurrently targeted by genetic changes in splenic marginal zone lymphomas. Haematologica 2012, 97:595-598.
39. Varettoni M., Arcaini L., Zibellini S., Boveri E., Rattotti S., Riboni R., et al. Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. Blood 2013, [Epub ahead of print]. 10.1182/blood-2012-09-457101.
40. Xu L., Hunter Z.R., Yang G., Zhou Y., Cao Y., Liu X., et al. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood 2013, 121:2051-2058.
41. Warner N., Núñez G. MyD88: a critical adaptor protein in innate immunity signal transduction. Journal of Immunology 2013, 190:3-4.
42. Aster J.C., Blacklow S.C., Pear W.S. Notch signalling in T-cell lymphoblastic leukaemia/lymphoma and other haematological malignancies. Journal of Pathology 2011, 223:262-273.
43. Lobry C., Oh P., Aifantis I. Oncogenic and tumor suppressor functions of Notchin cancer: it's NOTCH what you think. Journal of Experimental Medicine 2011, 208:1931-1935.
44. Welcker M., Clurman B.E. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nature Reviews Cancer 2008, 8:83-93.
45. Tanigaki K., Honjo T. Regulation of lymphocyte development by Notch signaling. Nature Immunology 2007, 8:451-456.
46. Yamamoto N., Yamamoto S., Inagaki F., Kawaichi M., Fukamizu A., Kishi N., et al. Role of Deltex-1 as a transcriptional regulator downstream of the Notch receptor. Journal of Biological Chemistry 2001, 276:45031-45040.
47. Pillai S., Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nature Reviews Immunology 2009, 9:767-777.
48. Santos M.A., Sarmento L.M., Rebelo M., Doce A.A., Maillard I., Dumortier A., et al. Notch1 engagement by Delta-like-1 promotes differentiation of B lymphocytes to antibody-secreting cells. Proceedings of the National Academy of Sciences of the United States of America 2007, 104:15454-15459.
49. Kuroda K., Han H., Tani S., Tanigaki K., Tun T., Furukawa T., et al. Regulation of marginal zone B cell development by MINT, a suppressor of Notch/RBP-J signaling pathway. Immunity 2003, 18:301-312.
50. Balatti V., Bottoni A., Palamarchuk A., Alder H., Rassenti L.Z., Kipps T.J., et al. NOTCH1 mutations in CLL associated with trisomy 12. Blood 2012, 119:329-331.
51. Del Giudice I., Rossi D., Chiaretti S., Marinelli M., Tavolaro S., Gabrielli S., et al. NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL. Haematologica 2012, 97:437-441.
52. López C., Delgado J., Costa D., Conde L., Ghita G., Villamor N., et al. Different distribution of NOTCH1 mutations in chronic lymphocytic leukemia with isolated trisomy 12 or associated with other chromosomal alterations. Genes, Chromosomes and Cancer 2012, 51:881-889.
53. Staudt L.M. Oncogenic activation of NF-kappaB. Cold Spring Harbor Perspectives in Biology 2010, 2:a000109.
54. Ruiz-Ballesteros E., Mollejo M., Rodriguez A., Camacho F.I., Algara P., Martinez N., et al. Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. Blood 2005, 106:1831-1838.
55. Malynn B.A., Ma A. A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme. Journal of Experimental Medicine 2009, 206:977-980.
56. Hu S., Du M.Q., Park S.M., Alcivar A., Qu L., Gupta S., et al. cIAP2 is a ubiquitin proteinligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. Journal of Clinical Investigation 2006, 116:174-181.
57. Rossi D., Gaidano G. ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter. Haematologica 2012, 97:5-8.
58. Wagner E.F., Nebreda A.R. Signal integration by JNK and p38 MAPK pathways in cancer development. Nature Reviews Cancer 2009, 9:537-549.
59. Tiacci E., Schiavoni G., Martelli M.P., Boveri E., Pacini R., Tabarrini A., et al. Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. Haematologica 2013, [Epub ahead of print]. 10.3324/haematol.2012.078071.
60. Arcaini L., Zibellini S., Boveri E., Riboni R., Rattotti S., Varettoni M., et al. The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood 2012, 119:188-191.
61. Tiacci E., Schiavoni G., Forconi F., Santi A., Trentin L., Ambrosetti A., et al. Simple genetic diagnosis of hairy cell leukemia by sensitive detection of the BRAF-V600E mutation. Blood 2012, 119:192-195.
62. Rossi D., Rasi S., Fabbri G., Spina V., Fangazio M., Forconi F., et al. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood 2012, 119:521-529.
63. Oscier D.G., Rose-Zerilli M.J., Winkelmann N., Gonzalez de Castro D., Gomez B., Forster J., et al. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood 2013, 121:468-475.
64. Rossi D., Rasi S., Spina V., Fangazio M., Monti S., Greco M., et al. Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome. British Journal of Haematology 2012, 158:426-429.
65. Villamor N., Conde L., Martínez-Trillos A., Cazorla M., Navarro A., Beà S., et al. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome. Leukemia 2012, [Epub ahead of print]. 10.1038/leu.2012.357.
66. Lim K.H., Yang Y., Staudt L.M. Pathogenetic importance and therapeutic implications of NF-κB in lymphoid malignancies. Immunological Reviews 2012, 246:359-378.
67. Wiestner A. Targeting B-Cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. Journal of Clinical Oncology 2013, 31:128-130.
68. Yang Y., Shaffer A.L., Emre N.C., Ceribelli M., Zhang M., Wright G., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21:723-737.
69. Follows G.A., Sims H., Bloxham D.M., Zenz T., Hopper M.A., Liu H., et al. Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib. British Journal of Haematology 2013, 161:150-153.
70. Dietrich S., Glimm H., Andrulis M., von Kalle C., Ho A.D., Zenz T. BRAF inhibition in refractory hairy-cell leukemia. New England Journal of Medicine 2012, 366:2038-2040.